Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections

Current Pharmaceutical Design

Volumn 12, Issue 16, 2006, Pages 2007-2015

  Bregenholt, Søren ^a   Jensen, Allan ^a   Lantto, Johan ^a   Hyldig, Sara ^a   Haurum, John S ^a  

^a Symphogen AS   (Denmark)

Author keywords

HIV; Infectious disease; Polyclonal antibodies; Recombinant antibodies; RSV; Vaccinia virus; Virus

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PALIVIZUMAB; POLYCLONAL ANTIBODY; RECOMBINANT HUMAN POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIGEN BINDING; BIOLOGICAL WARFARE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNE SYSTEM; NONHUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SMALLPOX VIRUS; UNSPECIFIED SIDE EFFECT; VACCINIA; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; AVIAN SARCOMA VIRUSES; BIOLOGICAL WARFARE; HIV; HUMANS; IMMUNIZATION, PASSIVE; ORTHOPOXVIRUS; RECOMBINANT PROTEINS; VIRUS DISEASES;

EID: 33744777491     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777442173     Document Type: Review

References (115)

1. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995; 21: 150-61.
2. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2: 695-703.
3. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2: 52-62.
4. Pollack P, Groothuis JR. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. J Infect Chemother 2002; 8: 201-6.
5. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.
6. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J 2003; 22: S46-S54.
7. Della-Porta AJ, Westway EG. A multi-hit model for the neutralization of animal viruses. J Gen Virol 1978; 38: 1-19.
8. Burton DR, Saphire EO, Parren PW. A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol 2001; 260: 109-43.
9. Martinez I, Melero JA. Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J Gen Virol 1998; 79: 2215-20.
10. Gerna G, Revello MG, Dovis M, Petruzzelli E, Achilli G, Percivalle E, et al. Synergistic neutralization of rubella virus by monoclonal antibodies to viral haemagglutinin. J Gen Virol 1987; 68: 2007-12.
11. Volk WA, Synder RM, Benjamin DC, Wagner RR. Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity. J Virol 1982; 42: 220-27.
12. Kingsford L. Enhanced neutralization of La Crosse virus by the binding of specific pairs of monoclonal antibodies to the G1 glycoprotein. Virology 1984; 136: 265-73.
13. Iorio RM, Bratt MA. Neutralization of Newcastle disease virus by monoclonal antibodies to the hemagglutinin-neuraminidase glycoprotein: requirement for antibodies to four sites for complete neutralization. J Virol 1984; 51: 445-51.
14. Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B. Development of a Cocktail of Recombinant-Expressed Human Rabies Virus-Neutralizing Monoclonal Antibodies for Postexposure Prophylaxis of Rabies. J Infect Dis 2003; 188: 53-6.
15. Sanna PP, Ramiro-Ibanez F, De Logu A. Synergistic interactions of antibodies in rate of virus neutralization. Virology 2000; 270: 386-96.
16. Mascola JR, Louder MK, vanCott TC, Sapan CV, Lambert JS, Muenz LR, et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol 1997; 71: 7198-206.
17. Li A, Baba TW, Sodroski J, Zolla-Pazner S, Gorny MK, Robinson J, et al. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses 1997; 13: 647-56.
18. Ciurea A, Hunziker L, Zinkernagel RM, Hengartner H. Viral escape from the neutralizing antibody response: the lymphocytic choriomeningitis virus model. Immunogenetics 2001; 53: 185-9.
19. Parren PW, Burton DR. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 2001; 77: 195-62.
20. Ciurea A, Hunziker L, Zinkernagel RM, Hengartner H. Viral escape from the neutralizing antibody response: the lymphocytic choriomeningitis virus model. Immunogenetics 2001; 53: 185-89.
21. Garcia-Barreno B, Portela A, Delgado T, Lopez JA, Melero JA. Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus. EMBO J 1990; 9: 4181-87.
22. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-312.
23. Witherell G. XTL-001. XTL Pharmaceuticals. Curr Opin Investig Drugs 2002; 3: 684-92.
24. Kuroiwa Y, Kasinathan P, Choi YJ, Naeem R, Tomizuka K, Sullivan EJ, et al. Cloned transchromosomic calves producing human immunoglobulin. Nature Biotechnol 2002; 20: 889-94.
25. Bird SM. Recipients of blood or blood products "at vCJD risk". BMJ 2004; 328: 118-9.
26. Hirsch MS, Curran JW. Human Immunedeficiency Virus. In: Fields BN, Knipe DM, Howley PM, et al. eds. Fields Virology. New York: Lipincott-Raven 1996; 1953-75.
27. Luciw P, Human Immunedeficiency Viruses and their replication. In: Fields BN, Knipe DM, Howley PM, et al. eds. Fields Virology. New York: Lipincott-Raven 1996; 1881-952.
28. Pereira CF, Paridaen JT. Anti-HIV drug development - an overview. Curr Pharm Des 2004; 10: 4005-37.
29. Ferrantelli F, Ruprecht RM. Neutralizing antibodies against HIV - back in the major leagues? Curr Opin Immunol 2002; 14: 495-502.
30. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6: 200-6.
31. Mascola JR, Stiegler G, vanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207-10.
32. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, Liska V, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001; 75: 7470-80.
33. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS -2003; 17: 301-9.
34. Vijh-Warrier S, Pinter A, Honnen WJ, Tilley SA. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J Virol 1996; 70: 4466-73.
35. Hovanessian AG, Briand JP, Said EA, Svab J, Ferris S, Dali H, et al. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. Immunity 2004; 21: 617-27.
36. Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, Zolla-Pazner S. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol 1994; 68: 4001-8.
37. Burton DR, Williamson RA, Parren PW. Antibody and virus: binding and neutralization. Virology 2000; 270: 1-3.
38. Parren PW, Mondor I, Naniche D, Ditzel HJ, Klasse PJ, Burton DR, et al. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 1998; 72: 3512-19.
39. Moreau E, Belliard G, Partidos CD, Pradezinsky F, Le Buanec H, Muller S, et al Important B-cell epitopes for neutralization of human immunodeficiency vinis type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides. J Gen Virol 2004; 85: 2893-901.
40. Lekkerkerker AN, Ludwig IS, van Vliet SJ, van Kooyk Y, Geijtenbeek TB. Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120. Virology 2004; 329: 465-76.
41. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-12.
42. Johnson WE, Sanford H, Schwall L, Burton DR, Parren PW, Robinson JE, et al. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol 2003; 77: 9993-10003.
43. Park EJ, Vujcic LK, Anand R, Theodore TS, Quinnan GV, Jr. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J Virol 1998; 72: 7099-107.
44. Ferrantelli F, Kitabwalla M, Rasmussen RA, Cao C, Chou TC, Katinger H, et al. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies - implications for acquired immunodeficiency syndrome vaccine. J Infect Dis 2004; 189: 71-4.
45. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 2002; 99: 6913-18.
46. Vose JM, Colcher D, Gobar L, Bierman PJ, Augustine S, Tempero M, et al. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 38: 91-101.
47. Darling RG, Catlett CL, Huebner KD, Jarret DG. Threats in bioterrorism. I: CDC category A agents. Emerg Med Clin North Am 2002; 20: 273-309.
48. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, et al. Smallpox as a Biological Weapon. JAMA 1999; 281: 2127-37.
49. Lane JM, Goldstein J. Evaluation of 21st Century risk of smallpox vaccination and policy options. Ann Intern Med 2003; 138: 488-93.
50. Breman JG, Henderson DA. Poxvirus dilemmas - monkeypox, smallpox, and biologic terrorism. N Engl J Med 1998; 339: 556-9.
51. Bray M. Pathogenesis of potential antiviral therapy for complications of small pox vaccination. Antiviral Res 2003; 58: 101-14.
52. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 1999; 254: 71-80.
53. Smith GL, Murphy BJ, Law M. Vaccinia virus motility. Ann Rev Microbiol 2003; 57: 323-42.
54. Moss B. Poxviridae: The viruses and their replication. 1996; 3: 2637-72.
55. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002; 83: 2915-31.
56. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 2002; 8: 833-41.
57. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 2003; 37: 251-71.
58. Xu R, Johnson AJ, Liggitt D, Bevan MJ. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004; 172: 6265-71.
59. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 2003; 100: 9458-63.
60. Boulter EA, Zwartouw HT, Titmuss DH, Maber HB. The nature of the immune state produced by inactivated vaccinia virus in rabbits. Am J Epidemiol 1971; 94: 612-20.
61. Davies DH, Liang X, Hernandez JE, Randall A, Hirst S, Mu Y, et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci USA 2005; 102: 547-52.
62. Law M, Smith GL. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 2001; 280: 132-42.
63. Bell E, Shamim M, Whitbeck JC, Sfyroera G, Lambris JD, Isaacs SN. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 2004; 325: 425-31.
64. Wyatt LS, Earl PL, Eller LA, Moss B. Highly attenuated Smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 2004; 101: 4590-5
65. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004; 428: 182-5.
66. Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 2003; 9: 1125-30.
67. Kidokoro M, Tashiro M, Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci USA 2005; 102: 4152-7.
68. Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 2003; 306: 181-95.
69. Hooper JW, Thompson E, Wilhelmsen C, Zimmerman M, Ichou MA, Steffen SE, et al. Smallpox DNA Vaccine Protects Nonhuman Primates against Lethal Monkeypox. J Virol 2004; 78: 4433-43.
70. Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 2004; 78: 10230-7.
71. Lustig S, Fogg C, Whitbeck JC, Moss B. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology 2004; 328: 30-5.
72. Aldaz-Carroll L, Whitbeck JC, de Leon MP, Lou H, Hirao L, Isaacs SN, et al. Epitope mapping studies define two major neutralization sites on the vaccinia virus EEV glycoprotein B5R. J Virol 2005; in press
73. Mullick J, Kadam A, Sahu A. Herpes and pox viral complement control proteins: "the mask of self". Trends Immunol 2003; 24: 500-7.
74. Isaacs SN, Kotwal GJ, Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci USA 1992; 89: 628-32.
75. Isaacs SN, Argyropoulos E, Sfyroera G, Mohammad S, Lambris JD. Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein. J Virol 2003; 77: 8256-62.
76. Collins PL, McIntosh K, Chanock RM. Respiratory Syncytial Virus. In: Fields BN, Knipe DM, Howley PM, et al. eds. Fields Virology. New York: Lipincott-Raven 1996; 1313-51.
77. Cane PA. Molecular epidemiology of respiratory syncytial virus. Rev Med Virol 2001; 11: 103-16.
78. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-86.
79. Collins PL, Mottet G. Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 1991; 72: 3095-101.
80. Levine S, Klaiber-Franco R, Paradiso PR. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol 1987; 68: 2521-4.
81. Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 1985; 151: 626-33.
82. Mufson MA, Orvell C, Rafnar B, Norrby E. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 1985; 66: 2111-24.
83. Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 2000; 13: 1-15.
84. Cane PA, Matthews DA, Pringle CR. Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses. J Gen Virol 1991; 72: 2091-6.
85. Sullender WM, Mufson MA, Anderson LJ, Wertz GW. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J Virol 1991; 65: 5425-34.
86. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997; 51: 151-78.
87. Garcia-Barreno B, Palomo C, Penas C, Delgado T, Perez-Brena P, Melero JA. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 1989; 63: 925-32.
88. Melero JA, Garcia-Barreno B, Martinez I, Pringle CR, Cane PA. Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. J Gen Virol 1997; 78: 2411-18.
89. Martinez I, Dopazo J, Melero JA. Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hyper-mutation events for the generation of antigenic variants. J Gen Virol 1997; 78: 2419-29.
90. Lopez JA, Bustos R, Orvell C, Berois M, Arbiza J, Garcia-Barreno B, et al. Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 1998; 72: 6922-8.
91. Zhao X, Chen FP, Sullender WM. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 2004; 318: 608-12.
92. Zhao X, Chen FP, Megaw AG, Sullender WM. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis 2004; 190: 1941-1946.
93. Zhao X, Sullender WM. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol 2005; 79: 3962-68.
94. Beeler JA, van Wyke CK. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989; 63: 2941-50.
95. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176: 1215-24.
96. Walsh EE, Hall CB, Schlesinger JJ, Brandriss MW, Hildreth S, Paradiso P. Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins. J Gen Virol 1989; 70: 2953-61.
97. Anderson LJ, Bingham P, Hierholzer JC. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol 1988; 62: 4232-38.
98. Hatta M, Kawaoka Y. The continued pandemic threat posed by avian influenza virus in Hong Kong. Trends Microbiol 2002; 10: 340-44.
99. Gould LH, Fikrig E. West Nile virus: a growing concern? J Clin Invest 2004; 113: 1102-7.
100. Groneberg DA, Poutanen SM, Low DE, Lode H, Welte T, Zabel P. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis 2005; 5: 147-55.
101. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287: 2391-405.
102. Chambers TJ, Diamond MS. Pathogenesis of flavivirus encephalitis. Adv Virus Res 2003; 60: 273-342.
103. Moran GJ. Threats in bioterrorism. II: CDC category B and C agents. Emerg Med Clin North Am 2002; 20: 311-30.
104. Bregenholt S, Haurum J. Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opin Biol Ther 2004; 4: 387-96.
105. Demkowicz WE, Maa JS, Esteban M. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. J Virol 1992; 66: 386-98.
106. Lai CF, Gong SC, Esteban M. The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. J Virol 1991; 65: 5631-35.
107. Hsiao JC, Chung CS, Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 1999; 73: 8750-61.
108. Wallengren K, Risco C, Krijnse-Locker J, Esteban M, Rodriguez D. The A17L gene product of vaccinia virus is exposed on the surface of IMV. Virology 2001; 290: 143-52.
109. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 2000; 266: 329-39.
110. Wolffe EJ, Vijaya S, Moss B. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 1995; 211: 53-63.
111. Gordon J, Mohandas A, Wilton S, Dales S. A prominent antigenic surface polypeptide involved in the biogenesis and function of the vaccinia virus envelope. Virology 1991; 181: 671-86.
112. Law M, Smith GL. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 2001; 280: 132-42.
113. Bleeker-Rovers CP, Boerman OC, Rennen HJ, Corstens FH, Oyen WJ. Radiolabeled compounds in diagnosis of infectious and inflammatory disease. Curr Pharm Des 2004; 10(24): 2935-50.
114. Picardi A, Gentilucci UV, Zardi EM, D'Avola D, Amoroso A, Afeltra A. The role of ribavirin in the combination therapy of hepatitis C virus infection. Curr Pharm Des 2004; 10(17): 2081-92.
115. Stoger E, Sack M, Nicholson L, Fischer R, Christou P. Recent progress in plantibody technology. Curr Pharm Des 2005; 11(19): 2439-57.